Shopping Cart
- Remove All
Your shopping cart is currently empty
GLPG2534
Catalog No. T75113Cas No. 2095615-97-5
Alias GLPG-2534
GLPG2534 is an orally active, selective and potent IRAK4 inhibitor with anti-inflammatory activity. GLPG2534 inhibits human and mouse IRAK4 and could be used to study psoriasis and atopic dermatitis.
GLPG2534
Catalog No. T75113Alias GLPG-2534Cas No. 2095615-97-5
GLPG2534 is an orally active, selective and potent IRAK4 inhibitor with anti-inflammatory activity. GLPG2534 inhibits human and mouse IRAK4 and could be used to study psoriasis and atopic dermatitis.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $113 | In Stock | |
| 5 mg | $278 | In Stock | |
| 10 mg | $455 | In Stock | |
| 25 mg | $886 | In Stock | |
| 50 mg | $1,450 | In Stock | |
| 100 mg | $2,320 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "GLPG2534"
ANTHRAQUINONE-2-CARBOXYLIC ACID
Cited
T7035117-78-2
Anthraquinone-2-carboxylic acid acts as a potent anti-inflammatory and antinociceptive component in vivo, thus contributing to the immune regulatory role of fruits and herbs.
- $40
Size
QTY
CitedThalidomide 4-fluoride
E3 ligase Ligand 4
T7755835616-60-9
Thalidomide 4-fluoride (E3 ligase Ligand 4) (Cereblon ligand 4) is the Thalidomide-based Cereblon ligand. Thalidomide 4-fluoride can be used in the recruitment of CRBN protein. Thalidomide 4-fluoride (Cereblon ligand 4) can be connected to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1.
- $29
Size
QTY
AS-2444697
T42991287665-60-4
AS-2444697 is an inhibitor of IRAK-4 (C50 = 21 nM). AS-2444697 exhibits renoprotective effects through anti-inflammatory action. AS-2444697 potently inhibits human and rat IRAK-4 activity.
- $30
Size
QTY
IRAK inhibitor 2
IRAK-IN-2
T7368928333-30-6In house
IRAK inhibitor 2 (IRAK-IN-2) is a potent inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK-4) for the study of inflammation-related diseases.
- $78
Size
QTY
Zimlovisertib
PF-06650833, PF06650833
TQ01671817626-54-2
Zimlovisertib (PF-06650833) is an effective, selective and orally active inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) (IC50s: 0.2 and 2.4 nM in the cell and PBMC assay).
- $39
Size
QTY
IRAK-1-4 Inhibitor I
IRAK-1/4 Inhibitor I, IRAK-1/4 Inhibitor
T2457509093-47-4
IRAK-1-4 Inhibitor I is a dual inhibitor targeting IRAK1 and IRAK4.
- $37
Size
QTY
Zabedosertib
BAY 1834845
T370761931994-81-8In house
Zabedosertib (BAY 1834845) is an inhibitor of IRAK4 with immunomodulatory potential. Zabedosertib protects against acute respiratory distress syndrome, a new study suggests.
- $36
Size
QTY
IRAK4-IN-1
T41401820787-94-7
IRAK4-IN-1 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.
- $64
Size
QTY
IRAK inhibitor 1
T50941042224-63-4
IRAK inhibitor 1 is an effective IRAK-4 inhibitor (IC50: 216 nM), is poorly active against JNK-1 (IC50: 3.801 μM) and JNK-2 (IC50>10 μM).
- $87
Size
QTY
JH-X-119-01
T92032227368-54-7
JH-X-119-01 is a highly potent and selective covalent inhibitor of IRAK-1 (Interleukin-1 Receptor-Associated Kinase 1).
- $60
Size
QTY
IRAK-4 protein kinase inhibitor 2
T9631301675-24-1
IRAK-4 protein kinase inhibitor 2 is a potent inhibitor of interleukin-1 receptor-associated kinase-4 (IC50 = 4 μM).
- $37
Size
QTY
IRAK4-IN-20
BAY-1834845
T627141931994-80-7
IRAK4-IN-20 is a potent and orally active IRAK4 inhibitor (IC50:3.55 nM). IRAK4-IN-20, which has anti-inflammatory, antitumor and anticancer effects, is often used to treat acute respiratory distress syndrome (ARDS).
- $195
Size
QTY
Select Batch
Purity:99.44%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | GLPG2534 is an orally active, selective and potent IRAK4 inhibitor with anti-inflammatory activity. GLPG2534 inhibits human and mouse IRAK4 and could be used to study psoriasis and atopic dermatitis. |
| Targets&IC50 | IL-1β:55 nM, IRAK1:179 nM, mIRAK4:3.5 nM, hIRAK4:6.4 nM |
| In vitro | GLPG2534 inhibits IL-6 release driven by IL-1β with an IC50 of 55 nM[1]. It also inhibits TNF-α-driven IL-6 release, with an IC50 of 6.6 μM[1]. When applied at concentrations ranging from 0.1 to 10 μM for 16 hours, GLPG2534 inhibits the expression of S100A7, DEFB4A, CXCL8, and TNF in ciliated epithelial cells stimulated with ciliogenesis-promoting factors[1]. |
| In vivo | GLPG2534, administered orally at doses ranging from 0.3 to 10 mg/kg, inhibits CL097-driven TNF-α release in mouse blood[1]. Furthermore, oral administration of GLPG2534 at doses of 10 and 30 mg/kg, twice daily, alleviates inflammation in a psoriasis-like mouse model[1]. Additionally, GLPG2534, at doses of 3-30 mg/kg, orally administered twice daily for 5 days, mitigates the development of IL-33 and MC903-induced atopic dermatitis-like skin inflammation in mice[1]. |
| Alias | GLPG-2534 |
| Molecular Weight | 424.45 |
| Formula | C21H24N6O4 |
| Cas No. | 2095615-97-5 |
Storage & Solubility Information
| Storage | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (188.48 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy GLPG2534 | purchase GLPG2534 | GLPG2534 cost | order GLPG2534 | GLPG2534 chemical structure | GLPG2534 in vivo | GLPG2534 in vitro | GLPG2534 formula | GLPG2534 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.